Skip Navigation


Schizophrenia Bulletin Advance Access originally published online on February 8, 2006
Schizophrenia Bulletin 2006 32(2):307-309; doi:10.1093/schbul/sbj049
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
32/2/307    most recent
sbj049v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chen, D. T
Right arrow Articles by Moreno, J. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, D. T
Right arrow Articles by Moreno, J. D
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.

Ethics of Medication-Free Research in Schizophrenia

Donna T Chen1,2–3, and Jonathan D Moreno3
2 Departments of Public Health Sciences and Psychiatric Medicine, Charlottesville, VA
3 Center for Biomedical Ethics, University of Virginia

The first 10% of the full text of this article appears below.

Bola's study highlights two important points about the ethics of medication-free research in early episode schizophrenia.1 First, the question of whether "biological toxicity" results from short periods of medication-free research in early episode schizophrenia is an important, though very narrow, question in the debate over ethics of medication-free research in schizophrenia. Second, even on this narrow question, the paucity of good data is striking.

Based on a meta-analysis of 623 participants in 4 randomized controlled trials and 3 quasi-experimental studies otherwise meeting his selection criteria for study inclusion, Bola concludes that "in the absence of substantive evidence of long-term harm from short periods of medication-free research in schizophrenia, a categorical prohibition of medication-free research in early episode schizophrenia on ethical grounds of harm to human subjects should probably be reconsidered." Instead, he suggests applying . . . [Full Text of this Article]


   Compelling Scientific Rationale
 

   "No Serious Harm or Significant Discomfort"
 

   Provisions to Minimize Risks of Harm
 
1To whom correspondence should be addressed; Center for Biomedical Ethics, Box 800758, University of Virginia Health System, Charlottesville, VA 22908, phone: 434-243-5804, fax: 434-982-3971, e-mail: dtc6k@virginia.edu.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?